The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCAT 2024 | The feasibility of hydroxyurea mobile directly observed therapy in patients with SCD in SSA
Enrico Novelli, MD, MS, University of Pittsburgh, Pittsburgh, PA, discusses the findings of a study comparing the use of mobile directly observed therapy versus standard monitoring to improve adherence to hydroxyurea in patients with sickle cell disease (SCD) in sub-Saharan Africa (SSA). Remote monitoring required patients to send selfie videos of medication intake to healthcare providers, and although adherence was high in both the intervention and control groups during the study in Tanzania, Dr Novelli emphasized the potential value of this method for long-term monitoring due to the widespread availability of smartphones. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisor/consultant for Novo Nordisk, Chiesi Pharmaceuticals and Shield Therapeutics.
